Targeting tumor blood vessels: An adjuvant strategy for radiation therapy

Radiotherapy and Oncology

Volumn 57, Issue 1, 2000, Pages 5-12

  Siemann, Dietmar W ^a   Warrington Jr , Kenneth H ^a   Horsman, Michael R ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Adjuvants to radiotherapy; Targeting; Tumor vasculature

Indexed keywords

ANGIOGENIC FACTOR; ANGIOSTATIN; ANTISENSE OLIGODEOXYNUCLEOTIDE; BASIC FIBROBLAST GROWTH FACTOR; COMBRETASTATIN; ENDOSTATIN; FLAVONE DERIVATIVE; METALLOPROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ZD 6126;

ANGIOGENESIS; DRUG RESEARCH; DRUG TARGETING; GENE THERAPY; HUMAN; MICROCIRCULATION; PRIORITY JOURNAL; RADIOTHERAPY; REVIEW; TREATMENT PLANNING; TUMOR VASCULARIZATION;

BLOOD VESSELS; CELL SURVIVAL; HUMAN; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SENSITIVITY AND SPECIFICITY; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0034306873     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(00)00243-7     Document Type: Review

References (111)

1. Evidence for mRNA expression of vascular endothelial growth factor by X-ray irradiation in a lung squamous carcinoma cell line
2. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
3. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis
4. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
5. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene
6. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
7. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome
8. Pretreatment oxygenation profiles of human soft tissue sarcomas
9. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma
10. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases
11. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents
12. Therapeutic significance of microenvironment factors
13. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate
14. A quantitative analysis of the reduction in oxygen levels required to induce up-regulation of vascular endothelial growth factor (VEGF) mRNA in cervical cancer cell lines
15. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid
16. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells
17. Hypoxia in tumors: a paradigm for the approach to biochemical and physiologic heterogeneity
18. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature
19. Vasculature as a target for tumour therapy
20. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy
21. Carcinoma of the cervix - anaemia, radiotherapy and hyperbaric oxygen
22. Keynote address: the influence of microenvironmental factors on the activity of radiation and drugs
23. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications
24. Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy
25. Tumor angiogenesis
26. How is blood vessel growth regulated in normal and neoplastic tissue?
27. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis
28. Tumor angiogenesis and tissue factor
29. Hypoxic stress proteins: survival of the fittest
30. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin
31. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation
32. An overview of clinical trials involving inhibitors of angiogenesis and their mechanisms of action
33. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors
34. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy
35. The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients
36. Breast cancer angiogenesis: therapy target and prognostic factor
37. Vinca alkaloids: anti-vascular effects in a murine tumour
38. Anti-vascular approaches to solid tumor therapy: evaluation of vinblastine and flavone acetic acid
39. 2 predicts survival in advanced cancer of the uterine cervix
40. Modifiers of tumor blood supply
41. The effect of combining flavone acetic acid and hyperthermia on the growth of a C3H mammary carcinoma in vivo
42. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumours
43. Antiangiogenesis treatment for gliomas: transfer of anti-sense vascular endothelial growth factor inhibits tumor growth in vivo
44. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma
45. Tumor angiogenesis: past, present and the near future
46. Angiopoietin-1 induces endothelial cell sprouting through the activation of focal adhesion kinase and plasmin secretion
47. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
48. Antiangiogenic agents
49. Inhibition of corneal neovascularization by alpha(v)-integrin antagonists in the rat
50. 2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix
51. Microvascular corrosion casting in the study of tumor vascularity: a review
52. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs
53. Effect of ionizing radiation on AP-1 binding activity and basic fibroblast growth factor gene expression in drug-sensitive human breast carcinoma MCF-7 and multidrug-resistant MCF-7/ADR cells
54. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy
55. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models
56. Colchine in the experimental chemotherapy of cancer
57. Combined effects of angiostatin and ionizing radiation in antitumour therapy
58. Oncogenic tranformation an hypoxia synergistically act to modulate vascular endothelial growth factor expression
59. Porphyrin photosensitization and phototherapy
60. Inhibitors of angiogenesis
61. Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells
62. Matrix metalloproteinases: biologic activity and clinical implications
63. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy
64. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck
65. Phosphorothioate oligonucleotides induction into experimental choroidal neovascularization by HVJ-liposome system
66. Vascular endothelial growth factor and lymph node metastasis in primary lung cancer
67. Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone
68. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
69. Angiostatin induces and sustains dormancy of human primary tumors in mice
70. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
71. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers
72. Potent synergism between vascular endothelial cell growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro
73. Therapeutic attack of hypoxic cells of solid tumors: presidential address
74. Early trials of antiangiogenic agents
75. Antiangiogenesis as a novel therapeutic concept in pediatric oncology
76. Current approaches to targeting cancer using antiangiogenesis therapies
77. Modification of chemotherapy by nitroimidazoles
78. The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities
79. Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells
80. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia
81. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity
82. The prognostic significance of tumor vascularization in patients with localized colorectal cancer
83. Flk-1 as a target for tumor growth inhibition
84. Pathophysiology of tumor angiogenesis and its relevance in renal cell cancer
85. Tumor hypoxia and heterogeneity: challenges and opportunities for the future
86. Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor
87. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease
88. Clinical practice of radiotherapy
89. Clinical trials of antiangiogenic agents
90. Effects of the novel alpha(v) integrin antagonist SM256 and cis-platinum on growth of murine squamous cell carcinoma PAM LY8
91. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review
92. Tumor oxygenation: characterization and clinical implications
93. Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma
94. Mapping of the vascular endothelial growth factor-producing hypoxic cells in multicellular tumor spheroids using a hypoxia-specific marker
95. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis
96. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy
97. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid
98. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy
99. The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells
100. Angiogenesis as an unfavorable factor related to lymph node metastasis in early gastric cancer
101. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding
102. Mouse endostatin inhibits the formation of lung and liver metastases
103. Suppression of hepatoma growth and angiogenesis by a fumagillin derivative TNP470: possible involvement of nitric oxide synthase
104. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells
105. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor
106. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid
107. Necrosis in non-tumour tissues caused by flavone acetic acid and 5,6-dimethylxanthenone acetic acid